Portal de Periódicos da CAPES

Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model

2021; Public Library of Science; Volume: 17; Issue: 3 Linguagem: Inglês

10.1371/journal.ppat.1009383

1553-7374

Drishya Kurup, Delphine C. Malherbe, Christoph Wirblich, Rachael Lambert, Adam J. Ronk, Leila Zabihi Diba, Alexander Bukreyev, Matthias J. Schnell,

COVID-19 Clinical Research Studies

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavirus that has caused a worldwide pandemic. Although human disease is often asymptomatic, some develop severe illnesses such as pneumonia, respiratory failure, and death. There is an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections accounting for up to 40% of transmission events. Here we further evaluated an inactivated rabies vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adjuvanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies and generated a strong Th1-biased immune response. Vaccinated hamsters were protected from weight loss and viral replication in the lungs and nasal turbinates three days after challenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the significant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic, and efficacious vaccine that warrants further assessment in human trials.